- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular Safety and Superiority of Anti-Obesity Medications
Authors
Keywords
-
Journal
Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
Volume Volume 14, Issue -, Pages 3199-3208
Publisher
Informa UK Limited
Online
2021-07-13
DOI
10.2147/dmso.s311359
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- STEP 1 for Effective Weight Control — Another First Step?
- (2021) Julie R. Ingelfinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
- (2020) Aaron S. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bias and Loss to Follow‐Up in Cardiovascular Randomized Trials: A Systematic Review
- (2020) Lucas Chun Wah Fong et al. Journal of the American Heart Association
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Safety and tolerability of new-generation anti-obesity medications: a narrative review
- (2018) Dhiren K Patel et al. POSTGRADUATE MEDICINE
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
- (2018) Stephen C. Bain et al. DIABETES OBESITY & METABOLISM
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gastric Bypass Surgery Produces a Durable Reduction in Cardiovascular Disease Risk Factors and Reduces the Long‐Term Risks of Congestive Heart Failure
- (2017) Peter N. Benotti et al. Journal of the American Heart Association
- Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential
- (2017) Michael E. Røder Therapeutic Advances in Chronic Disease
- Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release
- (2016) Bruno Halpern et al. Expert Opinion On Drug Safety
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide: A Review of Its Use in the Management of Obesity
- (2015) Lesley J. Scott DRUGS
- Why do we need observational studies of everyday patients in the real-life setting?: Table 1
- (2015) Alexander T. Cohen et al. EUROPEAN HEART JOURNAL SUPPLEMENTS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
- (2015) Darleen A. Sandoval et al. PHYSIOLOGICAL REVIEWS
- Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit
- (2014) Jonathan W. Cunningham et al. CLINICAL CARDIOLOGY
- American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease
- (2014) W. Garvey et al. Endocrine Practice
- Comparison of Treatment Effect Estimates From Prospective Nonrandomized Studies With Propensity Score Analysis and Randomized Controlled Trials of Surgical Procedures
- (2013) Guillaume Lonjon et al. ANNALS OF SURGERY
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?
- (2013) Andrew J. Krentz et al. DRUGS
- New advances in models and strategies for developing anti-obesity drugs
- (2013) Gilbert W Kim et al. Expert Opinion on Drug Discovery
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- (2012) Ele Ferrannini et al. Nature Reviews Endocrinology
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- A proposed clinical staging system for obesity
- (2009) A M Sharma et al. INTERNATIONAL JOURNAL OF OBESITY
- Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death
- (2008) Sebastian Schneeweiss et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery
- (2008) Dean A. Fergusson et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started